Production (Stage)
Genmab A/S
GMAB
$23.09
$0.462.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -22.33% | 12.76% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.33% | 12.76% | |||
| Cost of Revenue | -12.79% | 19.72% | |||
| Gross Profit | -22.85% | 12.40% | |||
| SG&A Expenses | -29.41% | 40.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.65% | 18.33% | |||
| Operating Income | -41.97% | 3.76% | |||
| Income Before Tax | -52.60% | 103.22% | |||
| Income Tax Expenses | 241.10% | -152.02% | |||
| Earnings from Continuing Operations | -64.51% | 194.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -64.51% | 194.55% | |||
| EBIT | -41.97% | 3.76% | |||
| EBITDA | -40.58% | 3.63% | |||
| EPS Basic | -94.87% | 194.38% | |||
| Normalized Basic EPS | -93.83% | 126.16% | |||
| EPS Diluted | -94.84% | 193.41% | |||
| Normalized Diluted EPS | -93.79% | 125.43% | |||
| Average Basic Shares Outstanding | 592.33% | 0.06% | |||
| Average Diluted Shares Outstanding | 587.82% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||